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Background: Acute coronary syndrome is the major cause of death in developed countries. Despite its high
prevalence, there is still a strong need for new biomarkers which permit faster and more accurate diagnostics and
new therapeutic drugs. The basis for this challenge lay in improving our understanding of the whole atherosclerotic
process from atherogenesis to atherothrombosis. In this study, we conducted two different proteomic analyses of
peripheral blood plasma from non-ST elevation acute coronary syndrome and ST elevation acute coronary syndrome
patients vs healthy controls.
Results: Two-dimensional Fluorescence Difference in Gel Electrophoresis and mass spectrometry permitted the
identification of 31 proteins with statistical differences (p < 0.05) between experimental groups. Additionally, validation
by Western blot and Selected Reaction Monitoring permitted us to confirm the identification of a different and
characteristic plasma proteomic signature for NSTEACS and STEACS patients.
Conclusions: We purpose the severity of hypoxia as the cornerstone for explaining the differences observed between
both groups.
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Acute coronary syndromes (ACS) remains the leading
cause of death in developed countries and presents an
increasing prevalence in developing countries [1]. Des-
pite its high prevalence, there is currently no biomarker
to detect the degenerative process that causes the ACS
before their clinical manifestation to appear.
In the last two decades there have been major ad-
vances in understanding the pathophysiology of athero-
genesis, especially through a better knowledge of the
role that inflammation plays in the different stages of
plaque development.
Currently, an increasing importance is assumed to the
study of the biology and activity of the atherosclerotic
plaque. Both factors are considered more important to
determine whether a lesion is going to produce an ACS
rather than the degree of luminal stenosis [2]. It has
been found that biologically active lesions have several* Correspondence: megonzalezb@sescam.jccm.es
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unless otherwise stated.characteristics that distinguish them from the more in-
active plaques. These include morphological and inflam-
matory features, which enhance a large infiltrate of
macrophages and lymphocytes, a high production of mol-
ecules that destroy the cytoskeleton of the plaque (cyto-
kines, metalloproteinases, etc.) and a decrease in protein
synthesis, such as collagen.
It is further known that an adaptive remodelling of the
injured artery accompanies the growth of the athero-
sclerotic plaque. At this stage, the analysis of the coron-
ary lumen does not identify any alteration, while analysis
of the arterial wall itself shows its existence. The pro-
gressive increase in our knowledge of the intimate rela-
tionship between inflammation and atherogenesis has
allowed a better understanding of the pathophysiology
of this disease [3,4]. It has additionally led to the appear-
ance of a large number of studies [5-10], which have dis-
covered potential biomarkers and new therapeutic
targets to establish a better and earlier diagnosis of the
disease and initiate appropriate treatment to improve
the prognosis of patient survival.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lished by the European Society of Cardiology (ESC) and
the American Heart Association (AHA) include the de-
termination of plasma levels of troponin and the heart
type creatine kinase isoenzyme (CKMB) [11]. However,
in both cases, their plasma levels are not elevated until
4–6 hours after onset of symptoms, which undoubtedly
leads a delay in diagnosis.
In this sense, it is necessary the identification of new
biomarkers transferable to clinical practice. Its introduc-
tion would help to establish an early diagnosis of the dis-
ease, could provide new therapeutic targets on which to
develop drugs, or could permit monitoring the evolution
of patients on a specific treatment and thus to establish
a correct prognosis.
In the present study, the objective was to discover
whether there was a common protein profile between
patients who have suffered a non-ST segment elevation
acute coronary syndrome (NSTEACS) and patients who
have suffered a ST segment elevation acute coronary
syndrome (STEACS) or whether the greater hypoxia at
which the myocardium is subjected in the second case
and consequently the greater extent of tissue necrosis pro-
duced the existence of a characteristic proteomic profile.
Why could be hypoxia important in ACS proteome?
Biochemical disorders that occur in ischemic heart dis-
ease are consequence of hypoxia. Under restricted oxy-
gen conditions, the muscular cells of the myocardium
obtain energy from anaerobic glycolysis, resulting in lac-
tate accumulation. This excess of lactate causes an intra-
cellular acidosis that leads to the activation of proteolytic
enzymes, to degradation of structural proteins responsible
for cardiac contractility, to the loss of integrity of the cell
membrane and, ultimately, to the release of proteins to
the blood and to the intercellular gap due to cell death.
In this process, the proteins that first appear in the cir-
culation are cytoplasmic (myoglobin and cytoplasmic
creatine kinase), followed by mitochondrial proteins
(mitochondrial creatine kinase) and structural proteins
(troponins and myosin). This explains why different
plasma levels of these current clinical biomarkers permit
the clinicians to theoretically classify the extension of
an ACS.
Results
The Differential In-gel Analysis (DIA) module detected
1293 and 1884 protein spots in the Two-dimensional
Fluorescence Difference in Gel Electrophoresis (2D-
DIGE) analysis of NSTEACS patients vs healthy controls
and STEACS patients vs healthy controls, respectively.
Statistical analysis revealed significant alterations in the
abundance of 47 protein spots (p < 0.05, 13 upregulated
and 34 downregulated, Table 1) and 24 protein spots(p < 0.05, 13 upregulated and 11 downregulated, Table 2),
respectively.
These differentially expressed spots were excised from
silver stained gels, digested with trypsin and analyzed by
MALDI-TOF/TOF. The ensuing database search identi-
fied 23 differentially expressed proteins in NSTEACS pa-
tients vs healthy controls and 11 in STEACS patients vs
healthy controls. The spot maps of both analyses are
shown in Figure 1 and complete data of identified spots
are shown in Tables 1 and 2.
Principal component analysis (PCA) was used to reduce
the complexity of the multidimensional dataset, providing
a clearer overview to better reveal trends within the data.
In both 2D-DIGE analyses, this analysis efficiently dis-
criminated NSTEACS (Figure 2A) or STEACS patients
(Figure 2B) from healthy controls plasma samples with
perfect separation of samples by the first principal compo-
nent (PC1). In this plot, healthy controls plasma samples
were scattered on the left side of the plot and NSTEACS
or STEACS plasma samples were located on the right.
The majority of proteins identified in both 2D-DIGE
analyses could be classified into seven functional categor-
ies (Figure 3), namely:Metabolism (~3.2%), Lipid Metabol-
ism and Transport (~29.3%), Inflammation and Immune
response (~25.8%), Blood homeostasis and coagulation
(~16.2%); Proteases and protease inhibitors (~9.7%), Others
(~6.4%) and Unknown (~6.4%). These functional categor-
ies were mainly determined using the Uniprot database:
1. Metabolism: Carbonic anhydrase.
2. Lipid metabolism and transport: ceruloplasmin,
apolipoprotein A-IV, vitamin D binding protein,
apolipoprotein E, apolipoprotein AI, retinol binding
protein 4 and hemopexin.
3. Inflammation and immune response: vitronectin,
ficolin 3, inter-alpha-trypsin inhibitor heavy chain
H1, inter-alpha-trypsin inhibitor heavy chain H2,
inter- alpha-trypsin inhibitor heavy chain H4,
complement C1r, alpha-1-antichymotrypsin,
kininogen-1, complement factor H, complement
factor H related protein-1 and fibronectin.
4. Blood coagulation and homeostasis: antithrombin III,
gamma fibrinogen, heparin cofactor 2, alpha-2-
macrogobulin and beta-2-glicoprotein 1.
5. Proteinase inhibitors and proteases: beta-Ala-His
dipeptidase, carboxypeptidase N catalytic chain and
kallistatin.
6. Others: haptoglobin and peroxiredoxin 2.
7. Unknown: alpha-1B-glicoprotein and leucine-rich
alpha-2-glycoprotein.
Annotation and functional enrichment
Functional analysis of the altered proteins was performed
using DAVID v6.7. Molecular functions and biological

















1 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4_HUMAN 143 1.68 103357.43 6.51 65501 4.98 Inflammation
2 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4_HUMAN 91 1.76 103357.43 6.51 65295 5.01 Inflammation
3 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4_HUMAN 81 1.51 103357.43 6.51 65226 5.03 Inflammation
4 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4_HUMAN 169 1.71 103357.43 6.51 65158 5.12 Inflammation
5 Ceruloplasmin CERU_HUMAN 100 1.52 122205.19 5.44 64849 5.18 Transport
6 Ceruloplasmin CERU_HUMAN 163 1.56 122205.19 5.44 67216 5.34 Transport
7 Complement factor H CFAH_HUMAN 102 -1.69 137052.59 6.12 66942 5.45 Immunity
8 Complement factor H CFAH_HUMAN 171 -1.53 137052.59 6.12 67045 5.47 Immunity
9 Complement factor H CFAH_HUMAN 242 -1.63 137052.59 6.12 67113 5.49 Immunity
10 Complement C1r subcomponent C1R_HUMAN 225 1.59 78213.16 5.76 60663 5.38 Inflammation
11 Alpha-1-antichymotrypsin AACT_HUMAN 104 3.16 47650.87 5.33 55105 4.94 Inflammation
11 Kininogen-1 KNG1_HUMAN 450 3.16 69896.70 6.23 55105 4.94 Inflammation
12 Antithrombin-III ANT3_PONAB 150 2.86 49039.14 5.95 54556 5.27 Coagulation
13 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4_HUMAN 165 -1.81 103357.43 6.51 51674 5.50 Inflammation
14 Beta-Ala-His dispeptidase CNDP1_HUMAN 431 1.53 56692.06 5.14 56477 4.68 Proteolysis
14 Vitronectin VTNC_HUMAN 221 1.53 54305.59 5.55 56477 4.68 Inflammation
14 Alpha-1-antichymotrypsin AACT_HUMAN 131 1.53 47650.87 5.33 56477 4.68 Inflammation
15 Gamma fibrinogen FIBG_HUMAN 182 -2.21 48483.03 5.24 49821 5.07 Coagulation
16 Ceruloplasmin CERU_HUMAN 173 -2.63 122205.19 5.44 45841 5.09 Transport
16 Apolipoprotein A-IV APOA4_HUMAN 121 -2.63 45399.06 5.28 45841 5.09 Transport
17 Vitamin D binding protein VTDB_HUMAN 163 -1.88 52963.65 5.40 47522 5.17 Transport
18 Hemopexin HEMO_HUMAN 140 -2.37 51676.37 6.55 44297 5.42 Transport
19 Complement factor H related protein-1 FHR1_HUMAN 188 -3.19 35738.20 7.10 44400 5.56 Inflammation
20 Catalytic chain carboxypeptidase N CBPN_HUMAN 228 -1.58 50034.39 6.88 44743 6.19 Peptidase
21 Leucin rich alpha-2-glicoprotein A2GL_HUMAN 143 -2.01 34346.41 5.66 45326 4.47 Unknown
22 Kininogen-1 KNG1_HUMAN 79 -1.71 69896.70 6.23 40969 4.53 Inflammation
23 Heparin cofactor 2 HEP2_HUMAN 103 -1.51 54960.02 6.26 36234 4.64 Coagulation
24 Complement C1r subcomponent C1R_HUMAN 105 -1.75 78213.16 5.76 35445 5.13 Inflammation
25 Apolipoprotein E APOE_HUMAN 87 -1.80 34236.68 5.52 35960 5.38 Transport
26 Ficolin-3 FCN3_HUMAN 127 -1.83 32902.98 6.22 36612 5.68 Inflammation
27 Complement factor H CFAH_HUMAN 199 -1.93 137052.59 6.12 36509 5.83 Inflammation
28 Complement factor H CFAH_HUMAN 169 -1.78 137052.59 6.12 36268 5.99 Inflammation
29 Antithrombin-III ANT3_HUMAN 138 -2.08 49039.14 5.95 21652 5.18 Coagulation
30 Apolipoprotein A-I APOA1_HUMAN 101 -2.68 28078.62 5.27 23333 5.48 Transport
31 Retinol binding protein 4 RET4_HUMAN 80 -1.52 21071.60 5.27 17844 5.61 Transport
32 Kininogen-1 KNG1_HUMAN 142 -2.37 69896.70 6.23 13452 4.68- Inflammation
33 Kininogen-1 KNG1_HUMAN 143 -2.37 69896.70 6.23 11016 4.82 Inflammation
34 Apolipoprotein A-IV APOA4_HUMAN 204 -2.97 45399.06 5.28 7173 4.74 Transport
35 Fibronectin FINC_HUMAN 185 1.66 259562.86 5.40 55654 5.98 Inflammation
35 Alpha-2-macroglobulin A2MG_HUMAN 174 1.66 160809.88 5.98 55654 5.98 Coagulation
PI: isoelectric point; MW: molecular weight; Prot score: score in MASCOT; Ratio P/C: variation between the patient group and the control group.
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1 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2_HUMAN 143 1.58 72452.28 5.75 105156 4.61 Inflammation
2 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2_HUMAN 91 1.74 72452.28 5.75 104880 4.62 Inflammation
3 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2_HUMAN 81 1.76 72452.28 5.75 104605 4.70 Inflammation
4 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2_HUMAN 127 1.56 72452.28 5.75 104605 4.72 Inflammation
5 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2_HUMAN 169 1.87 72452.28 5.75 104605 4.64 Inflammation
6 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2_HUMAN 162 2.01 72452.28 5.75 104743 4.67 Inflammation
7 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2_HUMAN 114 1.97 72452.28 5.75 104468 4.69 Inflammation
8 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2_HUMAN 126 1.51 72452.28 5.75 104468 4.74 Inflammation
9 Fibronectin FINC_HUMAN 181 -1.90 259562.86 5.39 95790 5.35 Inflammation
10 Inter-alpha-trypsin inhibitor heavy chain H1 ITIH1_HUMAN 123 1.53 71415.01 6.36 89463 5.75 Inflammation
11 Haptoglobin HPT_HUMAN 107 -2.79 43349.01 6.13 44644 5.16 Homeostasis
12 Alpha-1B-glicoprotein A1BG_HUMAN 218 -3.64 51921.66 5.63 44003 5.30 Unknown
13 Hemopexin HEMO_HUMAN 467 -8.90 4295.43 6.43 61518 5.92 Transport
14 Kallistatin KAIN_HUMAN 107 -2.27 46355.24 7.88 61115 5.95 Protease inhibitor
15 Beta-2-glicoprotien 1(ApoH) APOH_HUMAN 80 -2.80 36254.60 8.37 61035 6.09 Coagulation
16 Peroxiredoxin-2 PRDX2_HUMAN 131 -4.36 21760.73 5.67 18607 5.30 Anti-apoptosis
17 Antithrombin III ANT3_HUMAN 100 -4.23 49039.14 5.95 14232 5.44 Coagulation
18 Carbonic anhydrase CAH1_HUMAN 124 -5.02 28739.02 6.63 25844 6.17 Metabolism
PI: isoelectric point; MW: molecular weight; Prot score: score in MASCOT; Ratio P/C: variation between the patient group and the control group.
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tion tool to generate clusters of overrepresented Gene
Ontology (GO) terms. Molecular function analysis in
NSTEACS showed that a big number of the altered pro-
teins had enzyme inhibitor activity. High fold enrichment
was also related to immune response and inflammation.
Complement activation, homeostasis and coagulation to-
gether with immune response and inflammation are the
biological processes more representative in which altered
proteins are primarily involved.
Pathway analysis revealed a significant enrichment in In-
trinsic Prothrombin Activation Pathways (BIOCARTA) as
well as in complement and coagulation cascades (KEGG).
In the case of STEACS, pathways analysis did not reveal a
significant enrichment.
Functional annotation clustering tool was used to gather
molecular function and biological process results. Seven
significant clusters were obtained: inflammation and im-
mune response (enrichment score: 5.62), enzyme inhibitor
activity (enrichment score: 4.66), metabolism (2.96), re-
sponse (2.46), regulation (2.36) binding-related (enrichment
score: 2′3), and homeostasis (enrichment score: 2.19).
Protein-protein interaction
The 23 dysregulated proteins determined in the NSTEACS
2D-DIGE experiment were introduced into the web-tool
STRING v9.1 to generate protein-protein interactions net-
works. After clustering, seven functional modules formingtightly connected clusters can be observed (Figure 4A).
Regarding STEACS 2D-DIGE experiment, after clustering
two functional clusters were observed (Figure 4B).
Validation by Western blot
To confirm the proteomic results, western blot was
performed to antithrombin III (~49 kDa), alpha-1-
antiquimiotripsin (~48 kDa), hemopexin (~50 kDa), apo-
lipoprotein AI (~30 kDa), gamma fibrinogen (~48 kDa),
apolipoprotein E (~36 kDa), and kallistatin (~46 kDa)
using a densitometry software (Quantity One, BioRad).
In case of hemopexin and antithrombin III, these pro-
teins were validated in both, NSTEACS and STEACS
patients (Figure 5).
NSTEACS patients vs healthy controls
For antithrombin III, the analysis of band intensity
showed a statistically significant decreasing expression in
NSTEACS patients compared with healthy controls (p =
0.036). In the 2D western blot of alpha-1-antichymotryp-
sin several protein isoforms were observed. The two
isoforms that were found differentially expressed in the
2D-DIGE were also increased.
The 2D western blot of apolipoprotein E and hemopexin
confirmed the results obtained in the 2D-DIGE (−1.80
and −2.37, respectively) showing a decreasing expression
in NSTEACS patients. Gamma fibrinogen showed several
isoforms. The differentially reduced isoform found in the
Figure 1 Differential protein spots obtained in both 2D-DIGE analyses. (A) NSTEACS vs controls and (B) STEACS vs controls.
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of expression in the patient group NSTEACS. Similar re-
sults were obtained with apolipoprotein AI, where 2D
western blot confirmed the decreased expression levels in
patients with NSTEACS previously observed (−2.68).
STEACS patients vs healthy controls
The analysis of band intensity for antithrombin III,
hemopexin and kallistatin showed, in all three cases, aFigure 2 Score plots obtained in the PCA for data from the NSTEACSstatistically significant decrease in their expression levels
in patients with STEACS versus healthy controls with
significance values p = 0.0066, p = 0.0077 and p = 0.005 re-
spectively, confirming the results obtained in 2D-DIGE.
Validation by Selected Reaction Monitoring (SRM)
Additionally, in order to complete the validation of the
results obtained in the two previous proteomic analyses,
several proteins with altered expression profiles detectedvs controls (A) and STEACS vs controls (B) 2D-DIGE analyses.
Figure 3 Venn diagram showing the proteins identified in both 2D-DIGE analyses.
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SRM.
NSTEACS patients vs healthy controls
The proteins ceruloplasmin (p < 0.001 and p < 0.001), in-
ter alpha trypsin inhibitor heavy chain H4 (p = 0.019 and
p = 0.021), apolipoprotein E (p = 0.0087 and p = 0.0147),
vitamin D binding protein (p = 0.0208 and p = 0.0237)
and kininogen-1 (p = 0.0007 and p = 0.0163) showed
statistically significant differences in both peptides
after statistical analysis using a Student t-test (p < 0.05)
(Figure 6A).
Hemopexin (p = 0.0277 and p = 0.0591) and apolipo-
protein A-IV (p = 0.0173 and p = 0.1518) showed signifi-
cant differences in one of the two monitored peptides.
In the case of hemopexin, one of the two peptides was
very close to statistical significance (p = 0.0591) and
since it had been previously validated by western blot
this validation by SRM was accepted.
STEACS patients vs healthy controls
Similarly, an independent group of samples (n = 15
STEACS patients, n = 15 healthy controls) was used.
Alpha 1B-glycoprotein (p = 0.0029 and p = 0.0139), beta-
2 glycoprotein-1 (apo H) (p = 0.0047 and p = 0.0213),
peroxiredoxin 2 (p = 0.0003 and p = 0.0083), antithrom-
bin III (p = 0.0111 and p = 0.0234) and kallistatin (p =
0.0058 and p = 0.0179) showed statistically significant
differences in both peptides after statistical analysis
using Student’s t-test (Figure 6B). Results obtained forantithrombin III and kallistatin were validated by west-
ern blot and SRM.
Globally, the results obtained by these two different
validation methods confirmed those obtained from both
plasma proteomic analyses using the DIA module.
Discussion
Because of the current clinical tests for ACS just permits
its diagnosis after the onset of the syndrome, the discov-
ery of new biomarkers reflecting the development of the
atherosclerotic process results critical.
For studying potential candidates, it is previously ne-
cessary to consider the basic characteristic that every
clinical biomarker should meet; high sensitivity and high
specificity. Sensitivity, in many cases, depends on the
technique used and it usually improves with different
generations of reagents as it has happened with troponin
and ultrasensitive reactive C protein. Specificity, how-
ever, is a parameter that must be carefully considered
from the outset. In our study, we found a total number
of 31 altered proteins. Despite this apparently attractive
result, many of these proteins do not offer the previously
mentioned characteristic of an ideal biomarker. This
happens with vitamin D-binding protein (VDBP) and
the family of inter-alpha trypsin inhibitors which have
been related to different inflammatory diseases such as
rheumatoid arthritis, liver cirrhosis and Crohn’s disease
[12,13]. Since they have been also found altered in a
number of pathological states, their lack of specificity
prevents its clinical use for diagnosis of ACS.
Figure 4 Protein-protein interaction networks were studied using the STRING v9.1 web-tool. (A) NSTEACS Protein-Protein interaction
networks. (B) STEACS protein-Protein interaction networks. Different line colours represent the types of evidence for the association.
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Figure 5 Western blot validation. (A) NSTEACS vs controls and (B) STEACS vs controls.
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Fortunately, many of identified proteins are interesting
in terms of new biomarkers discovery or better under-
standing of physiopathology of ACS. In this sense, one
of the most remarkable results was the alteration of
three proteins with antioxidant properties; haptoglobin,
1B-glycoprotein and peroxiredoxin-2 [14,15]. In all cases,
decreased plasma levels were found in STEACS patients.
Therefore, we consider that this alteration could triggerthe damage caused by reactive oxygen species (ROS) due
to the lack of protective antioxidant effect [16-18]. Simi-
larly, decreased levels of ceruloplasmin and hemopexin
could produce an increase of free oxygen promoting tissue
oxidation during the atherogenic process due to its ability
to catalyse the reduction of oxygen molecules [19] and
protect against oxidation of the LDL caused by hemopro-
teins, respectively [16,17]. In this group of proteins whose
decreased plasma levels may predispose to suffer ACS, we
Figure 6 SRM validation. (A) NSTEACS vs controls and (B) STEACS vs controls. The yellow narrow shows the SRM transition of interest.
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serine protease inhibitors with various effects including
powerful vasodilator activity, inhibition of angiogenesis
and anti-inflammatory activity [20-22].
Extensively known is the role of apolipoproteins in the
metabolism and transport of cholesterol. We found sev-
eral apolipoproteins; ApoA-I, ApoA-IV, ApoE and ApoH
with decreased plasma levels in ACS patients. Due to their
biological functions, their alterations could favour the ap-
pearance of a pro-thrombotic state and the progression of
atherosclerosis [23-27].
Coagulation is a basic phase in ACS onset. Fibrinogen
and antithrombin III are currently used in clinical prac-
tice for the diagnosis of different coagulation alterations.
In this group of proteins we also include kininogen-1, a
multifunctional protein that participates in the intrinsic
pathway of the coagulation as a part of the kallikrein-
kinin system [28,29] inhibiting platelet aggregation in-
duced by thrombin and plasmin [30,31]. We hypothesize
that decreased plasma levels of kininogen-1 couldpromote platelet aggregation and trigger the progression
of atherosclerosis.
One of the most exciting results that we observed in
the STEACS plasma proteome was the alteration of car-
bonic anhydrase. This protein catalyses the rapid conver-
sion of carbon dioxide and water to bicarbonate and free
protons to maintain the acid–base balance in the blood
and other tissues. It decreased levels in STEACS patients
permits us to postulate that tissue hypoxia carries a car-
diac muscle intracellular acidosis situation caused by the
production of lactic acid derived from anaerobic glycoly-
sis. This state of acidosis would modify the reaction
equilibrium in the opposite direction catalysed by the
enzyme to prevent the formation and release of higher
acid content in the cells. Since carbonic anhydrase was
altered in STEACS but not in NSTEACS patients, its de-
creased plasma levels may have potential to differentiate
the extent of cardiac necrosis in ACS.
In summary, ACS is a multifactorial disease in which
several processes contribute to the development of the
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the possibility of defining a single diagnostic biomarker. In
contrast, a panel of biomarkers reflecting these processes
could help clinicians to correctly and individually diagnose
the risk of every patient of suffering an ACS. In our opin-
ion, this panel should be formed by proteins related to
oxidative damage (i.e. hemopexin and ceruloplasmin), co-
agulation (i.e. kininogen-1 and antithrombin III) and hyp-
oxia (carbonic anhydrase), which were all of them found
altered in this study.Future lines of research
The results obtained in this study also permits to picture
some interesting lines of research for the future. The re-
lationship between different cardiovascular diseases such
as ACS and aortic stenosis (AS) could be elucidated
through a deeper knowledge of the plasma proteome. In
this sense, we obtained statistical differences in two pro-
teins; alpha-1-antichymotrypsin and leucine-rich alpha-
2-glycoprotein that we had previously found altered in
AS [32]. We believe that these two proteins could play a
role in the development of both inflammatory pathologies
and permit us to suggest new lines of research to study
the possible relationship between AS and atherosclerosis
and the differences between these two processes.Table 3 Baseline characteristics of healthy controls and











Age (years) ± SD 64.2 ± 11,5 68.3 ± 9.8 67.1 ± 8.7
Sex (Male/Female) 17/18 27/8 21/6
Risk factors
Smokers 3 10 9
Ex-smokers 3 8 7
Diabetes mellitus 1 5 7
Dyslipidemia 6 23 17
Hypertension 14 22 22
Renal disease 0 3 3
Biochemical data
Total cholesterol (mg/ 182 ± 37 165 ± 27 172 ± 28
LDL (mg/dL) 103 ± 36 99 ± 28 109 ± 31
HDL (mg/dL) 50 ± 12 49 ± 8 47 ± 9
Triglycerides (mg/dL) 123 ± 50 144 ± 59 161 ± 43
Background data
Previous ACS 0% 8 4
Statins 0% 17 10Conclusions
In the present study, our results from both 2D-DIGE
analyses permitted us to suggest that NSTEACS patients
had a characteristic plasma proteomic profile that differ-
entiates them from those patients who have suffered a
STEACS. Although in both 2D-DIGE experiments some
patients had previously suffered ACS, as it was explained
in detail in the Material and method section any previous
disease or surgery should have occurred in a six months
period before being included in the study. In our opinion,
this period of time is broad enough to consider that the
existence of a previous ACS in any patient would have no
influence on the protein pattern found in our studies.
Additionally, in spite of the large variety of biological
processes of the identified proteins, based on our previ-
ous experience in secretome studies, the tissue is the ori-
gin of many of them [33,34]. As previously explained in
the Background section, the wide number of biochem-
ical disorders secondary to hypoxia suffered by the myo-
cardium lead to tissue breakdown and the releasing of a
large number of proteins of potential interest into the
blood stream. In fact, among the proteins forming the char-
acteristic plasma proteomic profile for STEACS patients
appeared decreased expression levels of three proteins with
antioxidant activity (1B-glycoprotein, peroxiredoxin-2 and
haptoglobin) which will possible catalyze the damage
caused by the plasma ROS in the endothelium. In spite ofa direct NSTEACS vs STEACS 2D-DIGE would probably
confirm these results, we are strongly confident that the
global proteome described in this study permit us to sug-
gest the need to consider the use of a panel of biomarkers
as the most useful tool for early diagnosis of ACS.
Methods
Patient selection and sample collection
The study was conducted according to the Declaration
of Helsinki and it was approved by the ethics committee
of the Hospital Virgen de la Salud (Toledo). All the pa-
tients and controls signed an informed consent before
their inclusion in the study.
Three experimental groups were selected: 1) NSTEACS
patients, 2) STEACS patients and 3) healthy controls. Blood
samples (K3 EDTA) of NSTEACS and STEACS patients
and sex and age matched healthy subjects were recruited
from the Cardiology Service of Hospital Virgen de la Salud
(Toledo, Spain). In case of ACS patients, the samples were
obtained in the onset of the syndrome (t = 0 h) defined as
the moment when the coronary event is diagnosed.
Different pathologies and situations were considered
as exclusion criteria. Tumour inflammatory diseases, al-
terations of coagulation, the existence of significant heart
disease unrelated to the disease or its risk factors (valvu-
lar, pericardial affectations or cardiomyopathies), chronic
treatments, except for ischemic heart disease and its risk
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less than 0.45, major trauma, thromboembolic events,
revascularization or having undergone surgery within six
months before the start of the study. The control group
included 30 healthy volunteers with normal coronary ar-
teries and up to two cardiovascular risk factors who
attended the Department of Hemodynamic for various
reasons. All healthy volunteers and patients had a sex
and age distribution with no significant differences be-
tween them (Table 3).
Depletion of high-abundant plasma proteins
In order to increase the concentration of low-abundant
proteins in plasma samples, the 14 most abundant
plasma proteins were specifically removed by affinity
chromatography using the Multiple Affinity Removal
Column (MARS Hu-14, Agilent Technologies). This
technique has proven to be an interesting tool in the
search for plasma biomarkers [32,35,36].
Depletion was performed by high performance liquid
chromatography (HPLC) using a 1200 series HPLC chro-
matograph (Agilent Technologies) equipped with a man-
ual injector (9725i, Agilent Technologies). After several
chromatographic cycles, aliquots of the flow-through frac-
tions containing low-abundance proteins were combined
and desalted using centrifugal filter devices with a 3 kDa
cut off (Amicon Ultra, Millipore). These samples were
stored at -80°C prior to analysis and the protein con-
centration was determined using the Bradford-Lowry
method [37].
Two-dimensional differential in gel electrophoresis
(2D-DIGE)
NSTEACS plasma samples (n = 5) and healthy control
samples (n = 5) or STEACS plasma samples (n = 6) and
healthy control samples (n = 6) with similar clinical pa-
rameters were used in both 2D-DIGE analyses. This
technique is based on the specific linkage of three fluo-
rochromes with differential spectral properties (Cy2, Cy3
and Cy5). It permits the separation of multiple samples
in a single gel increasing the reproducibility and reliabil-
ity of the analysis of differential expressed proteins.
Proteins were labelled according to the manufacturer’s
instructions (GE Healthcare), such that 50 μg of de-
pleted plasma proteins from NSTEACS or STEACS pa-
tients and healthy controls were labeled with 400 pmol
of N-hydroxysuccinimide Cy3 or Cy5 fluorescent cya-
nine dye and the labeling reaction was then quenched
with 0.2 mM lysine. All experiments included an internal
standard containing equal amounts of each protein ex-
tract labeled with 400 pmol of N-hydroxysuccinimide
Cy2 dye. The internal standard and two additional
plasma samples (NSTEACS/STEACS and control) were
combined and run on a single gel (150 μg of totalprotein). Protein extracts were diluted in rehydration
buffer (30 mM TRIS, 7 M Urea, 2 M Thiourea, 4%
CHAPS) and applied to 24 cm pH 4–7 IPG strips. The
first dimension was run on the IPGphor IEF II System
(GE Healthcare) in darkness, as follows: 500 V for 30 mi-
nutes, a linear gradient to 3500 V over 3 h, 3500 V for 3 h,
a linear gradient to 6000 V over 3 h, and 6000 V until
69000 v/h. After the first dimension, the strips were equili-
brated in SDS-equilibration buffer (1.5 M Tris/HCl
[pH 8.8], 6 M Urea, 87% Glycerol and 2% SDS).
To increase the reproducibility an electrophoresis sys-
tem “Ettan DALTsix” (GE Healthcare) was used for the
polymerization of the gels. To run the second dimension
10% acrylamide gels were used. To do this, 1.5 M Tris–
HCl pH 8.8 was used, 10% SDS (w/v) and milliQ water
were used to obtain the desired concentration of acryl-
amide. APS and TEMED (BioRad) were also added to
catalyst the polymerization reaction. After preparing the
gels, each IPG strip was placed horizontally on the top
of the gel, avoiding bubbles to remain trapped between
the strip and the surface of the gel. Electrophoresis took
place at 25°C, firstly applying 5 W/gel for 20 min and
then 1 W/gel overnight in the presence of running buf-
fer (25 mM Tris, 0.2 M glycine, 3 mM SDS).
Image acquisition and analysis
After SDS-PAGE, the gels were scanned on a Typhoon
TRIO fluorescence gel scanner (GE Healthcare) using
appropriate individual excitation and emission wave-
lengths, filters and photomultiplier values sensitive for
each of the Cy3, Cy5 and Cy2 dyes.
Relative protein quantification was performed on
NSTEACS and STEACS patients and healthy control
samples using DeCyder software v6.5 (GE Healthcare)
and the multivariate statistical Extended Data Analysis
(EDA) module. The DIA module simultaneously de-
tected the 3 images of each gel (the internal standard
plus two samples), measured the spot abundance in each
image, and expressed these values as Cy3/Cy2 and Cy5/
Cy2 ratios. These DIA datasets were then analysed using
the Biological Variation Analysis (BVA) module, which
matched the spot maps and compared the Cy3/Cy2 and
Cy5/Cy2 ratios. Differences in protein abundance >1.5-
fold were considered significant. Statistical analysis using
Student’s t-test was performed to detect changes in pro-
tein expression, with p ≤ 0.05 accepted as significant.
Finally, a multivariate analysis was performed through
a Principal Component Analysis (PCA) using the algo-
rithm included in the EDA module of DeCyder software
based on the spots that matched across all gels.
Conventional two-dimensional electrophoresis (2-DE)
For the protein spots identification 2-DE gels were used.
Plasma samples were diluted in rehydration buffer and
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equilibrated as previously described [32,38,39]. For the
second-dimension separation, 10% SDS-PAGE was per-
formed according to Laemmli [40] using a Protean II sys-
tem (BioRad) at 4°C and 25 mA/gel. The gels were fixed
overnight and Silver Stained (GE Healthcare) following
the manufacturer’s instructions and finally scanned with a
GS-800 Calibrated Densitometer (BioRad).
Protein identification by MALDI-TOF/TOF and database
searching
Protein spots from 2-DE gels were excised manually, auto-
matically digested with an Ettan Digester (GE Healthcare)
and identified at the Proteomic Unit of Hospital Nacional
de Paraplejicos. In-gel trypsin digestion was performed
according to Schevchenko et al. [41] with minor modifica-
tions. Peptides were extracted with 60% acetonitrile
(ACN) in 0.1% formic acid (99.5% purity; Sigma Aldrich).
Samples were dried in a speed vac and re-suspended in
98% water with 0.1% formic acid (FA) and 2% ACN. An
aliquot of each digestion was mixed with an aliquot of the
matrix solution (3 mg/mL matrix α-cyano-4-Hydroxycin-
namic acid: CHCA, Sigma Aldrich) in 30% ACN, 15% 2-
propanol and 0.1% TFA, and this was pipetted directly
onto the stainless steel sample plate of a 384 Opti-TOF
123 × 81 mm MALDI mass spectrometer (ABsciex) and
dried at room temperature. MALDI-MS/MS data were
obtained using an automated analysis loop in a 4800 Plus
MALDI TOF/TOF Analyzer (ABsciex).
MALDI-MS and MS/MS data were combined using
GPS Explorer Software Version 3.6 to search a non-
redundant protein database (Swissprot 56.5) with the
Mascot software version 2.2 (Matrix Science) applying the
following settings: 50 ppm precursor tolerance, 0.6 Da
MS/MS fragment tolerance, 1 missed cleavage allowed,
carbamidomethylcysteines (variable) and methionine oxi-
dation (fixed) as modifications. The MALDI-MS/MSTable 4 Resume of primary and secondary antibodies used for
times
Protein Primary antibody Dilution Incuba
Gamma fibrinogen Abcam 1:20000 1 ho
Hemopexin (NSTEACS) Abcam 1:2000 1 ho
Apolipoprotein E Abcam 1:500 1 ho
Antithrombin III (NSTEACS) Abcam 1:2000 1 ho
Alpha-1 antichymotrypsin Abcam 1:2000 1 ho
Apolipoprotein AI Polyclonal 1:50000 1 ho
Coagulation Factor XII Abcam 1:1000 1 ho
Antithrombin III (STEACS) Abcam 1:2000 1 ho
Hemopexin (STEACS) Abcam 1:200 1 ho
Kallistatin Abcam 1:2000 1 hospectra and database search results were manually
inspected in detail using the previous software.
Pathways analysis
Functional classification and protein interactions were
investigated using publicy available bioinformatics tools:
Database for Annotation, Visualisation and Integrated
Discovery (DAVID v6.7) and Search Tool for the Re-
trieval of Interacting Genes/Proteins (STRING v9.1).
DAVID bioinformatics provides an integrated biological
knowledgebase and analytic tools aimed at systematically
extracting biological meaning from large gene/protein lists
derived from high-throughput experiments. STRING is a
database and web resource dedicated to protein–protein
interactions, including both physical and functional inter-
actions, that maps all interaction evidence onto a common
set of genomes and proteins. Proteins with different ex-
pression between IS patients and control were uploaded
to DAVID and STRING for functional and protein inter-
action analyses, respectively.
Western blot
For the validation process, independent groups of sam-
ples from healthy controls and NSTEACS or STEACS
patients were used. All samples were depleted and quan-
titated using the Bradford-Lowry method [37]. One-
dimensional (1D) and two-dimensional (2D) western
blots were used.
20 ug of protein from every depleted plasma sample
were mixed with loading buffer (10% SDS, 87% glycerol,
2-mercaptoethanol 5% Bromophenol blue and 0.002%
Tris -HCl 0.5 M pH 6.8) and heated at 95°C for 5 min
before application on the gel wells.
Then, electrophoresis was performed using SDS-PAGE
different percentages of acrylamide/bisacrylamide (be-
tween 8 and 12% acrylamide), depending on the ex-
pected molecular mass of the protein to be analyzed.western blot validation along with dilutions and incubation
tion Secondary antibody Dilution Incubation
ur - - -
ur Rabbit True blood eBioscience 1:1000 45 min
ur IgG antigoat donkey HRP Abcam 1:2000 45 min
ur Mouse True blood eBioscience 1:1000 45 min
ur Mouse True blood eBioscience 1:1000 45 min
ur Rabbit True blood eBioscience 1:10000 45 min
ur Rabbit True blood eBioscience 1:10000 45 min
ur Mouse True blood eBioscience 1:1000 45 min
ur Rabbit True blood eBioscience 1:10000 45 min
ur Rabbit True blood eBioscience 1:10000 45 min
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performed as described by Laemmli protocol [40] and
immobilization was carried out onto nitrocellulose
membranes (BioRad) by semi-dry transfer (BioRad) for
30 min at 20 V, using transfer buffer (25 mM Tris,
151.8 mM glycine and 20% methanol v/v). Then, the
nitrocellulose membranes were stained by immersing
them in a solution of Ponceau Red S (Sigma) in 0.2%
trichloroacetic acid 30% (w/v) sulfosalicylic acid and 30%
(w/v) for 1 min, washed with distilled water to remove
excess dye and a scanned with the densitometer (GS-800
Calibrated Densitometer, BioRad). To check the perform-
ance of the transfer gels were stained with Coomassie
blue. Once the proteins immobilized on nitrocellulose
membranes, these were blocked in a solution of skimmed
milk powder 7.5% (w/v) in PBS/ 0.1% Tween20 overnight
at 4°C under stirring. After blocking, all subsequent steps
were performed at room temperature and under stirring.
The membranes washed three times for 10 min with
washing buffer PBS/ 0.1% Tween20. The membranes were
incubated for 1 hour with the specific primary antibody di-
luted in PBS/0.1% Tween20 (Table 4). After making three
washes of 10 min in wash buffer, the membranes were in-
cubated for 45 min with the appropriate secondary anti-
body diluted in PBS/ 0.1% Tween20. Finally, repeated
three washes of 10 min and revealed using the method
based chemiluminescent oxidation of luminol by the ac-
tion of hydrogen peroxide catalyzed by horseradish perox-
idase (ECL Western Blotting Detection Reagents, GE
Healthcare). Computer-assisted densitometric image ana-
lysis of digital subtraction images was performed to quan-
tify the proteins. Student’s t-test (p < 0.05) was used for the
statistical analysis of data.
Selected reaction monitoring
Crude plasma samples were reduced, digested and cleaned
with Pep-Clean spin columns (Pierce) according to the
manufacturer’s instructions prior to mass spectrometry
(MS) analysis in the LC-MS/MS system. It consisted of a
TEMPO nano LC system (Applied Biosystems) combined
with a nano LC Autosampler coupled to a modified triple
quadrupole (4000 QTRAP LC/MS/MS, Applied Biosys-
tems). Theoretical SRM transitions were designed using
MRMpilot software v1.1 (ABSciex). An independent group
of 15 controls and 15 NSTEACS or STEACS patients
were analyzed in the 4000QTrap using a MIDAS acquisi-
tion method that included the theoretical transitions.
Statistical analysis
A Kolmogorov-Smirnov test demonstrated the normal
distribution of the population analyzed. A Levene test
for homogeneity of variance was performed and the Stu-
dent t-test was used to compare band intensities. SRM
statistical analysis was carried out using the GraphPadPrism 4.0 software package and for all tests statistical
significance was accepted when p < 0.05.
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